Sandoz pulls injectable methotrexate due to particulate matter

05/22/2013 | MedPage Today (free registration)

Sandoz recalled two lots of its methotrexate sodium USP, 25 mg/mL, 40 mL vial injectable drug, which is indicated for rheumatoid arthritis, severe psoriasis and neoplastic diseases. The drugmaker found particulate matter in vials of lots CL0996 and CJ4948 while performing a routine quality inspection. Parenteral injection of the recalled products "can lead to microembolisation in areas where the particles lodge," the FDA warned in a press release.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC